Back to Newsroom

Sigilon Therapeutics to Present at the 2017 Cell & Gene Meeting on the Mesa

CAMBRIDGE, Mass., Sept. 29, 2017 – Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced that Devyn Smith, Ph.D., Sigilon Therapeutics Chief Strategy Officer and Head of Operations, will present an overview of the company’s development programs at the Cell & Gene Meeting on the Mesa to be held Oct. 4-6, 2017, in La Jolla, California. Presentation details are as follows: